Epicur caps 30 mg pack cont cell/pack card x14


Indications for use

Epicurus is used as part of complex therapy for various diseases in which the level of acidity in the stomach is disturbed.

Such pathologies include:

  • erosions and ulcers of the stomach and duodenum caused by treatment with non-steroidal anti-inflammatory drugs or infection with Helicobacter pylori;
  • stomach ulcer, duodenal ulcer;
  • functional dyspepsia;
  • reflux esophagitis;
  • stress ulcer;
  • erosive and ulcerative esophagitis;
  • Zollinger-Ellison syndrome.

Mode of application


Epicurus capsules should be swallowed whole and not chewed. The dosage and duration of administration are selected by the doctor depending on the diagnosed disease.

In case of exacerbation of duodenal ulcer, patients take 30 mg of the drug (1 capsule) per day. If there is no or insufficient effect, the daily dosage is increased to 60 mg (2 capsules). The average duration of treatment is 7-14 days.

For acute gastric ulcers and erosive-ulcerative esophagitis, take 30 mg, and with increased body resistance - up to 60 mg of the drug per day for 4-8 weeks.

For ulcers and erosions of the gastrointestinal tract due to taking NSAIDs, patients are prescribed 30 mg of the drug per day. The duration of therapy can range from 4 to 8 weeks.

When eradicating Helicobacter pylori, take 30 mg 2 times a day, the course is about two weeks. Treatment in this case must be comprehensive in combination with antibiotics.

To prevent relapses of stomach and duodenal ulcers, patients are advised to take 30 mg of the drug per day. The duration of therapy is determined by the doctor individually.

To prevent relapses of reflux esophagitis, take 30 mg of medication per day. Patients are prescribed long-term treatment, the duration of which can reach six months.

The dosage for Zollinger-Ellison syndrome is selected on an individual basis. In this case, it is necessary to reduce basal secretion to a level of less than 10 mmol/h.

Release form, composition

Epicurus is available in capsules containing white spherical microgranules. They are packaged in contour blister packs of 7 pieces (in a cardboard pack - from 1 to 4 such packs) or 10 pieces (in a cardboard pack - 2-3 blister packs).

Each capsule contains 30 mg. lansoprazole.

Interaction with other drugs

Lanzoprazole, being an active component of Epicurus, increases the time of elimination from the body of diazepam, indirect anticoagulants, phenytoin, the metabolism of which occurs in the liver through microsomal oxidation.


In addition, under the influence of the active substance, the clearance of theophylline decreases by 10%, the rate of pH-dependent absorption of drugs of weak acids decreases, and the pH-dependent absorption of drugs from the base group is accelerated.

When Epicur is used simultaneously with sucralfate, the bioavailability of lansoprazole is reduced by 30%. In this regard, drugs must be taken at intervals of 30-40 minutes.

Under the influence of antacids, the absorption of lansoprazole is reduced and slowed down. These medications must be taken 1 hour before or 2-3 hours after Epicurus.

Epicur caps 30 mg No. 14

Compound

Active substance: lansoprazole - 30 mg.
Excipients: sugar pellets (sucrose), sugar syrup (sucrose), mannitol, calcium carboxymethylcellulose (calcium carmellose), magnesium carbonate, sodium disubstituted phosphate (sodium hydrogen phosphate), sodium lauryl sulfate, polyvinylpyrrolidone K-30 (povidone), Tween 80 (polysorbate 80), hydroxypropyl methylcellulose (hypromellose), acrylic coating L30DA (methacrylic acid), talc, polyethylene glycol 6000 (macrogol), titanium dioxide, sodium hydroxide.

Hard gelatin capsules (quinoline yellow [E 104], patent blue V, gelatin) methyl parahydroxybenzoate, propyl parahydroxybenzoate).

Pharmacokinetics

Absorption is high, bioavailability is 80% (food intake reduces absorption and bioavailability by 50%, but the inhibitory effect on gastric secretion remains the same, regardless of food intake).

The time for maximum concentration (Cmax) after oral administration of 30 mg is 1.5-2.2 hours, Cmax is 0.75-1.15 mg/l. Bonding with plasma proteins is 97.7-99.4%. Actively metabolized during the initial passage through the liver. The half-life is 1.3-1.7 hours. Excretion by the kidneys (in the form of metabolites) - 14-23% and through the intestines. In liver failure and in elderly patients, excretion slows down.

Indications for use

  • Peptic ulcer of the stomach and duodenum.
  • Reflux esophagitis, erosive and ulcerative esophagitis.
  • Erosive and ulcerative lesions of the stomach and duodenum associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), stress ulcers.
  • Erosive and ulcerative lesions of the stomach and duodenum associated with Helicobacter pylori (as part of complex therapy).
  • Zollinger-Ellison syndrome.

Contraindications

Hypersensitivity to the components of the drug, malignant neoplasms of the gastrointestinal tract, pregnancy (first trimester), lactation period, age under 18 years.

With caution: Hepatic and/or renal failure, pregnancy (II-III trimester), old age.

Directions for use and doses

Inside. Capsules should be swallowed whole without chewing.

Duodenal ulcer in the acute phase - 30 mg per day for 2-4 weeks (in resistant cases up to 60 mg per day).

Gastric ulcer in the acute phase and erosive-ulcerative esophagitis - 30-60 mg per day for 4-8 weeks.

Erosive and ulcerative lesions of the gastrointestinal tract caused by taking NSAIDs - 30 mg per day for 4-8 weeks.

Eradication of Helicobacter pylori - 30 mg 2 times a day for 10-14 days in combination with antibacterial agents.

Anti-relapse treatment of gastric and duodenal ulcers - 30 mg per day.

Anti-relapse treatment of reflux esophagitis - 30 mg per day for a long time (up to 6 months).

Zollinger-Ellison syndrome - the dose is selected individually until the basal secretion level is less than 10 mmol/h.

Storage conditions

In a dry place, protected from light and out of reach of children, at a temperature not exceeding 25 °C.

Best before date

2 years. Do not use the drug after the expiration date indicated on the package.

special instructions

Before starting treatment, it is necessary to exclude the presence of a malignant process in the upper gastrointestinal tract, since taking the drug can “mask” symptoms and complicate diagnosis.

Description

Gastric gland secretion-lowering agent - proton pump inhibitor.

Pharmacodynamics

Antiulcer agent. Specific inhibitor of the proton pump (H+K+ATPase); metabolized in the parietal cells of the stomach to active sulfonamide derivatives, which inactivate the sulfhydryl groups of H+K+ATPase. Blocks the final stage of hydrochloric acid synthesis, reducing basal and stimulated secretion, regardless of the nature of the stimulus. Inhibition of hydrochloric acid production at a dose of 30 mg is 80-97%. Does not affect gastrointestinal motility. The inhibitory effect increases in the first four days of administration. After stopping the intake, acidity remains below 50% of the basal level for 39 hours, and there is no “rebound” increase in secretion. Secretory activity is restored 3-4 days after stopping the drug. In patients with Zollinger-Ellison syndrome, the effect lasts longer.

Side effects

From the digestive system: increased or decreased appetite, nausea, abdominal pain; rarely - diarrhea or constipation; in some cases - ulcerative colitis, candidiasis of the gastrointestinal tract, increased activity of liver enzymes, increased levels of bilirubin in the blood.

From the nervous system: headache; rarely - malaise, dizziness, drowsiness, depression, anxiety.

From the respiratory system: rarely - cough, pharyngitis, rhinitis, upper respiratory tract infection, influenza-like syndrome.

From the hematopoietic organs: rarely - thrombocytopenia (with hemorrhagic manifestations); in some cases - anemia.

Allergic reactions: skin rash; in some cases - photosensitivity, erythema multiforme.

Other: rarely - myalgia, alopecia.

Interaction

Slows down the elimination of drugs metabolized in the liver by microsomal oxidation (including diazepam, phenytoin, indirect anticoagulants).

Reduces the clearance of theophylline by 10%.

Changes the pH-dependent absorption of drugs belonging to the groups of weak acids (deceleration) and bases (acceleration).

Sucralfate reduces the bioavailability of lansoprazole by 30% (it is necessary to observe an interval of 30-40 minutes between taking these drugs)

Antacids slow down and reduce the absorption of lansoprazole (they should be prescribed 1 hour before or 1-2 hours after taking lansopoazole).

Side effects

As a result of taking Epicurus, a number of side effects were identified that affect both the physical and mental state of the patient:

  1. From the central nervous system - dizziness and headaches, daytime drowsiness, anxiety, depression, general weakness.
  2. From the gastrointestinal tract - nausea and stomach pain, diarrhea, constipation, appetite disorders.
  3. From the respiratory system - cough, rhinitis, pharyngitis (very rarely).
  4. From the hematopoietic system - thrombocytopenia with hemorrhagic manifestations (rarely), anemia (very rarely).
  5. Allergic manifestations include skin rash (sometimes), photosensitivity and erythema multiforme (very rarely).

Contraindications

Epicurus should not be taken if you are hypersensitive to lansoprazole. The risk of complications also increases when treating patients over 65 years of age with the drug.

During pregnancy

Epicurus is not prescribed to women during the first trimester of pregnancy , or during breastfeeding.

At later stages of pregnancy, taking the drug is allowed, but first the doctor must assess the possible risks to the fetus.

Epicurus instructions for use

Directions for use : Take the drug orally. Swallow the capsules without chewing. To eradicate Helicobacter pylori, take 30 mg twice a day. Combination with antibiotics (amoxicillin and clarithromycin) for at least seven days. For the treatment of duodenal ulcers and stress ulcers, take 30 mg per dose, 1 time per day. The drug should be taken in the morning for 2 to 4 weeks. For the treatment of gastric ulcers and erosive-ulcerative esophagitis, take 30 mg per day for 4 - 8 weeks (as prescribed by a doctor - 60 mg per day). To treat reflux esophagitis, take 30 mg per day for 4 weeks. For the treatment of Zollinger-Ellison syndrome, the dosage is selected by the doctor according to individual indications. For the treatment of non-ulcer dyspepsia, the dosage is 15-30 mg per day. The course lasts from 2 to 4 weeks. Side effects Identified from the central nervous system (can manifest themselves in the form of headache, dizziness, malaise, depression, drowsiness, anxiety); from the digestive system (may manifest itself as a decrease or increase in appetite, nausea, abdominal pain, diarrhea, constipation); from the respiratory system (extremely rarely they can manifest themselves in the form of cough, pharyngitis, rhinitis); from the hematopoietic system (rarely they can manifest themselves in the form of thrombocytopenia, which is accompanied by hemorrhagic manifestations, in isolated cases - anemia); allergic reactions (skin rash, in isolated cases - photosensitivity, erythema multiforme).

Contraindications Epicur is contraindicated in patients with hypersensitivity to its components. The drug is contraindicated for patients in the first trimester of pregnancy and during breastfeeding (lactation).

Pregnancy The drug should not be used by patients in the first trimester of pregnancy, as well as during breastfeeding (lactation). During the second and third trimesters of pregnancy, Epicur can only be taken as prescribed by a doctor.

Drug interactions The active substance slows down the excretion of drugs that are metabolized in the liver by microsomal oxidation (diazepam, indirect anticoagulants, phenytoin). Reduces the clearance of theophylline by 10%, slows down the pH-dependent absorption of drugs belonging to the group of weak acids, accelerates the pH-dependent absorption of drugs belonging to the group of bases. Sucralfate reduces the bioavailability of lansoprazole by 30% (when taken simultaneously): the recommended interval between taking these drugs is 30 - 40 minutes. Antacids tend to slow down and reduce the absorption of lansoprazole, so it is recommended to prescribe them one hour before or 2-3 hours after taking lansoprazole.

Overdose To date, cases of overdose of the drug Epicur have not been recorded.

Release form Capsules. The contents of the capsules are white spherical microgranules.

Storage conditions The shelf life of the drug is 2 years. Epicurus should be stored in a dry place, protected from light. The temperature should not exceed 25 degrees Celsius.

Composition One capsule contains lansoprazole pellets (353 mg), lansoprazole content - 30 mg.

Pharmacological group Medicines used for diseases of the gastrointestinal tract Medicines used to treat gastric and duodenal ulcers Proton pump inhibitors

Active ingredient: Lansoprazole

Additionally, the drug is available with a prescription.

Price

The cost of Epicurus varies depending on the region of sale. It is produced by a Russian company, so in the Russian Federation its price is lower than in other countries.

Average price in Russia

In Russia, a package of the drug containing 14 capsules of 30 mg can be purchased at a price of around 400 rubles.

Average cost in Ukraine

In Ukraine, a package of Epicurus of 14 capsules of 30 mg each costs an average of 200 hryvnia.

Video on the topic: Duodenal ulcer

Rating
( 1 rating, average 4 out of 5 )
Did you like the article? Share with friends:
For any suggestions regarding the site: [email protected]
Для любых предложений по сайту: [email protected]